In the context of dual-targeting agents—especially those directed at both integrin αvβ3 and 64Cu-GRPR—this approach has demonstrated favorable pharmacokinetics and strong tumor uptake, offering high-contrast imaging potential. Here, GRPR is linked to neoplasm.